Table 2.

Cox regression model of mortality from the time of measurement of baseline mesothelin

VariableUnivariateModel AaModel Bb
HR (95% CI)PHR (95% CI)PHR (95% CI)P
Mesothelin (per 5 nmol/L increase)1.04 (0.96–1.11)NS1.09 (1.00–1.19)0.0381.01 (0.92–1.11)NS
Mesothelin grouped (cf. <1 nmol/L)
 (1–5 nmol/L)1.35 (0.80–3.31)NS1.48 (0.79–2.78)NS1.45 (0.76–2.75)NS
 (>5 nmol/L)2.25 (1.20–4.21)0.0112.31 (1.11–4.81)0.0251.42 (0.61–3.32)NS
S creatinine (per unit increase)0.99 (0.97–1.00)0.0660.98 (0.96–0.99)0.0060.99 (0.98–1.01)NS
Age (per year increase)1.02 (1.00–1.04)NS1.04 (1.01–1.19)0.0111.04 (1.01–1.07)0.017
Gender (females cf. males)0.47 (0.38–1.47)NS0.58 (0.27–1.24)NS0.48 (0.21–1.10)NS
Treatment (cf. none)
 Pemetrexed0.87 (0.41–1.77)NS1.25 (0.58–2.68)NS0.73 (0.28–0.98)NS
 Gemcitabine0.96 (0.54–1.72)NS0.74 (0.41–1.32)NS0.52 (0.28–0.98)0.045
Histology (cf. epitheloid)
 Biphasic1.11 (0.60–2.04)NS1.19 (0.73–2.54)NS0.90 (0.46–1.75)NS
 Sarcomatoid3.65 (1.61–8.29)0.0024.41 (1.89–10.29)0.0013.40 (1.28–9.00)0.014
Pleurodesis (cf. not done)0.87 (0.52–1.46)NS1.15 (0.62–2.11)NS
CT stage (cf. stage I)
 Stage II1.21 (0.40–3.65)NS
 Stage III1.61 (0.75–3.48)NS
 Stage IV2.21 (1.04–4.68)0.04
PET measurements
 Volume (per 1,000 unit increase)1.50 (1.15–1.95)0.0031.77 (1.23–2.54)0.002
 TGV (per 1,000 unit increase)1.08 (1.02–1.13)0.0031.11 (1.03–1.19)0.003

Abbreviation: NS, not significant.

  • aMesothelin, measured at the time of diagnosis, was entered into the model as a categorical or as a trend variable. Survival was measured from the time of diagnosis.

  • bMesothelin, measured at the time of the PET scan, was entered into the model as a categorical or as a trend variable. Either TGV or volume was entered into the model. Adjusted mesothelin result shown is after adjustment for PET volume. A similar result for mesothelin after adjustment for the TGV was observed.